Articles from Meiji Seika Pharma Co., Ltd.

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Toshiaki Nagasato) today announced a strategic equity investment in Lyric Bio, Inc. (Head Office: San Carlos, USA, founded by Chief Executive Officer: Kayj Shannon and Chief Scientific Officer Melanie Matheu). Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand.

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter “Meiji”) announced that the company has concluded an investment agreement with MPM BioImpact LLC, a Boston-based biotech investment firm (hereafter “MPM BioImpact”). Meiji has committed to invest USD 20 million in MPM BioImpact’s new technologies and virology strategy as a strategic partner and aims to broaden Meiji’s perspective on early-stage opportunities and enhance its global network.

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi), a leading Japanese pharmaceutical company specializing in infectious diseases, vaccines, and hematology, announced today that it has established a new office in the Boston area, USA, and is initiating venture investments in the life science and healthcare fields. Through its investment activities, Meiji Seika Pharma aims to discover and develop cutting-edge therapies and contribute to solving unmet medical needs of patients worldwide, reflecting the company’s unwavering commitment to innovation and global health.

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced that positive findings from the phase II clinical trial of ME3183, a novel highly-potent selective phosphodiesterase-4 (PDE4) inhibitor, in patients with plaque psoriasis conducted in the United States and Canada (NCT05268016) were presented on 12 October at the European Association of Dermatology and Venereology (EADV) Congress 2023 held in Berlin.

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced that ME3183, a novel highly-potent selective phosphodiesterase-4 (PDE4) inhibitor, met the primary endpoint based on “PASI-75”, defined as the proportion of subjects achieving 75% improvement in Psoriasis Area Severity Index (PASI), in phase II clinical trial in patients with moderate-to-severe plaque psoriasis conducted in the United States and Canada.

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) and the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan, President: Tasuku Honjo, hereinafter ‘FBRI’) announce the discovery of a novel anti-PD-1 agonist monoclonal antibody, which can induce immunosuppressive effect, through their collaborative research on “Treatment of inflammatory diseases, including autoimmune diseases, through the immunosuppressive activity of PD-1” (HBI* Innovation Program) conducted at the FBRI's Dept. of Immunology, Institute of Biomedical Research and Innovation (Professor: Akio Ohta). Part of the findings from the above research was published in "Science Immunology**" issued on January 13, 2023 (Eastern Standard Time). For more information, please visit the FBRI website (URL: https://www.fbri-kobe.org/kbic/english/pressrelease/2023_01-16/). Meiji Seika Pharma and FBRI are working together to develop the above PD-1 agonist monoclonal antibody as therapeutic candidate for autoimmune diseases.

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi, hereinafter “Meiji”) today announced that the first patient was dosed in Phase II clinical trial of ME3183, a selective phosphodiesterase-4 (PDE4) inhibitor, in patients with plaque psoriasis in the United States and Canada.

Meiji Seika Pharma Co., Ltd.* (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi, hereinafter “Meiji”) today announced that it has successfully completed Phase I clinical trials of ME3183, a selective PDE4 inhibitor, conducted in the United States. ME3183 has been shown to be safe and well-tolerated across the doses tested.

First paragraph, third sentence of release dated May 20, 2021, should read: Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: JUNG Jae-Hun, “Dong-A”). (instead of Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: Jong Hyun Han, “Dong-A”).).

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi, “Meiji”) today announced that the bioequivalence of DMB-3115, a proposed ustekinumab biosimilar, has been demonstrated in phase I clinical trial compared to the reference products marketed in Europe and the United States. Meiji also announced the initiation of phase III multi-regional clinical trial in patients with plaque psoriasis. Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: Jong Hyun Han, “Dong-A”).